We are live on ! Find out more
RYTM icon

Rhythm Pharmaceuticals
RYTM

285 hedge funds and large institutions have $6.42B invested in Rhythm Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 64 funds opening new positions, 101 increasing their positions, 89 reducing their positions, and 51 closing their positions.

New
Increased
Maintained
Reduced
Closed

776% more call options, than puts

Call options by funds: $16.4M | Put options by funds: $1.87M

25% more first-time investments, than exits

New positions opened: 64 | Existing positions closed: 51

13% more repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 89

2% more funds holding

Funds holding: 279 → 285 (+6)

0% more funds holding in top 10

Funds holding in top 10: 10 → 10 (0)

1.43% less ownership

Funds ownership: 109.17% → 107.74% (-1.4%)

18% less capital invested

Capital invested by funds: $7.8B → $6.42B (-$1.38B)

Holders
285
Holders Change
+6
Holders Change %
+2.15%
% of All Funds
3.51%
Holding in Top 10
10
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.12%
New
64
Increased
101
Reduced
89
Closed
51
Calls
$16.4M
Puts
$1.87M
Net Calls
+$14.5M
Net Calls Change
+$1.06M

Top Buyers

1
Citadel Advisors
Citadel Advisors
Florida
+$123M
2
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$64.4M
3
PCH
Polar Capital Holdings
United Kingdom
+$41.8M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$40.6M
5
Bank of America
Bank of America
North Carolina
+$39.3M

Top Sellers

1
NMC
NEA Management Company
Maryland
-$311M
2
Jennison Associates
Jennison Associates
New York
-$98.3M
3
DCM
Driehaus Capital Management
Illinois
-$82.5M
4
Federated Hermes
Federated Hermes
Pennsylvania
-$32.8M
5
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$26.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$61.2M +$5.11M +52,576 +8%
RSCM
27
Rock Springs Capital Management
Maryland
$60M -$512K -5,262 -0.8%
Pictet Asset Management
28
Pictet Asset Management
Switzerland
$57.3M +$5.09M +52,383 +9%
Bank of America
29
Bank of America
North Carolina
$54.7M +$39.3M +404,183 +180%
Franklin Resources
30
Franklin Resources
California
$54.5M -$6.7M -68,890 -10%
ClearBridge Investments
31
ClearBridge Investments
New York
$53M +$10M +103,328 +20%
IHAM
32
Integral Health Asset Management
New York
$52.2M +$12.2M +125,000 +26%
UBS AM
33
UBS AM
Illinois
$47.1M -$736K -7,570 -1%
Charles Schwab
34
Charles Schwab
California
$45.8M -$582K -5,988 -1%
Northern Trust
35
Northern Trust
Illinois
$43.4M +$1M +10,298 +2%
Loomis, Sayles & Company
36
Loomis, Sayles & Company
Massachusetts
$40.4M -$3.77M -38,799 -8%
CS
37
Candriam SCA
Luxembourg
$40.4M +$17.2M +176,433 +61%
Millennium Management
38
Millennium Management
New York
$39.3M +$25.8M +265,116 +142%
SI
39
Sofinnova Investments
California
$39.1M +$17.4M +178,702 +66%
LGM
40
Logos Global Management
California
$39.1M +$25.3M +260,000 +137%
DCM
41
Driehaus Capital Management
Illinois
$38M -$82.5M -848,676 -66%
VFT
42
Vanguard Fiduciary Trust
Pennsylvania
$36.7M +$41M +421,911 New
OM
43
Opaleye Management
Massachusetts
$35.3M -$20.1M -207,000 -63%
Artisan Partners
44
Artisan Partners
Wisconsin
$34M +$12.4M +127,078 +48%
Ameriprise
45
Ameriprise
Minnesota
$33.4M +$11.9M +122,797 +47%
Invesco
46
Invesco
Georgia
$31.7M +$7.11M +73,156 +25%
Lord, Abbett & Co
47
Lord, Abbett & Co
New Jersey
$30.3M -$26.3M -270,589 -44%
O
48
OrbiMed
New York
$27.3M +$7.23M +74,300 +31%
B
49
Braidwell
Connecticut
$27M +$30.2M +310,628 New
SCM
50
Silverarc Capital Management
Massachusetts
$26.6M +$16.5M +170,050 +125%
1
2
3 4 5

RYTM Hedge Fund Activity: Q1 2026 in Review

285 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q1 2026, worth a combined $6.42B — down 18% from $7.8B a quarter earlier.

Buyers outnumbered sellers: 64 funds opened new RYTM positions and 51 closed out — a net gain of 13 holders — while 101 added to existing stakes and 89 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $123M. The largest seller was NEA Management Company, exiting entirely with an estimated $311M sold.

  • 285 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q1 2026, up from 279 in Q4 2025.
  • Funds reported $6.42B of Rhythm Pharmaceuticals stock for Q1 2026, down 18% quarter-over-quarter.
  • 64 funds opened new Rhythm Pharmaceuticals positions in Q1 2026 and 51 closed out, a net change of +13 holders.
  • The largest Rhythm Pharmaceuticals buyer in Q1 2026 was Citadel Advisors, an estimated $123M added.
  • The largest Rhythm Pharmaceuticals seller in Q1 2026 was NEA Management Company, an estimated $311M sold.

Based on aggregated 13F filings for Q1 2026.